Cell-Based In Vitro Assay Automation: Balancing Technology and Data Reproducibility/Predictability.


Journal

SLAS technology
ISSN: 2472-6311
Titre abrégé: SLAS Technol
Pays: United States
ID NLM: 101697564

Informations de publication

Date de publication:
Jun 2020
Historique:
pubmed: 1 2 2020
medline: 15 7 2021
entrez: 1 2 2020
Statut: ppublish

Résumé

G-protein-coupled receptors (GPCRs) are modulated by many marketed drugs, and as such, they continue to be key targets for drug discovery and development. Many GPCR targets at Merck Research Laboratories (MRL) are profiled using homogenous time-resolved fluorescence (HTRF) inositol monophosphate (IP-1) cell-based functional assays using adherent cells in 384-well microplates. Due to discrepancies observed across several in vitro assays supporting lead optimization structure-activity relationship (SAR) efforts, different assay paradigms were evaluated for removing growth medium from the assay plates prior to compound addition and determination of IP-1 accumulation. Remarkably, employing the noncontact centrifugation BlueWasher method leads to left-shifted potencies across multiple structural classes and rescues "false negatives" relative to the traditional manual evacuation method. Further, assay performance is improved, with the minimum significant ratio of challenging chemotypes dropping from ~5-6 to <3. While the impact of BlueWasher on a broad range of our GPCR targets remains to be determined, for highly protein-bound small molecules, it provides a path toward improving assay reproducibility across scientists and sites as well as reducing replicates in SAR assay support.

Identifiants

pubmed: 32003291
doi: 10.1177/2472630320902095
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

276-285

Auteurs

Brande Thomas-Fowlkes (B)

Screening, Target and Compound Profiling, Merck Research Labs, Merck & Co., Inc., Kenilworth, NJ, USA.
Global Clinical Trials Operations, Merck & Co., Inc., Kenilworth, NJ, USA.

Steven Cifelli (S)

Screening, Target and Compound Profiling, Merck Research Labs, Merck & Co., Inc., Kenilworth, NJ, USA.

Sarah Souza (S)

In Vitro Pharmacology, Merck Research Labs, Merck & Co., Inc., Kenilworth, NJ, USA.
Evotec AG, Princeton Junction, NJ, USA.

Richard Visconti (R)

In Vitro Pharmacology, Merck Research Labs, Merck & Co., Inc., Kenilworth, NJ, USA.
Celgene Corporation, Summit, NJ, USA.

Alice Struck (A)

Screening, Target and Compound Profiling, Merck Research Labs, Merck & Co., Inc., Kenilworth, NJ, USA.

Adam Weinglass (A)

Screening, Target and Compound Profiling, Merck Research Labs, Merck & Co., Inc., Kenilworth, NJ, USA.

Mary Jo Wildey (MJ)

Screening, Target and Compound Profiling, Merck Research Labs, Merck & Co., Inc., Kenilworth, NJ, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH